PMID- 32039015
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 9
DP  - 2019
TI  - Self-Reported Burden in Elderly Patients With Localized Prostate Cancer Treated 
      With Stereotactic Body Radiation Therapy (SBRT).
PG  - 1528
LID - 10.3389/fonc.2019.01528 [doi]
LID - 1528
AB  - Purpose: Retaining quality of life in patients treated with SBRT for prostate 
      cancer remains paramount. As such, balancing the benefits of treatment against 
      the effects of therapy on elderly patients is essential. The EORTC QLQ-ELD14 
      (ELD-14) is a validated questionnaire with a domain dedicated to burden of 
      illness and treatment in the elderly. The Expanded Prostate Cancer Index 
      Composite (EPIC)-26 is a validated questionnaire which measures urinary, bowel, 
      sexual, and hormonal symptoms. This study reports trends in self-reported burden 
      in patients with prostate cancer treated with SBRT and reveals convergence of 
      self-reported burden with treatment related side effects obtained from the 
      EPIC-26 questionnaire. Methods: All patients >/=70 years old, with localized 
      prostate cancer treated with SBRT +/- ADT at Medstar Georgetown University Hospital 
      from 2013 to 2018 and had completed the ELD-14 were eligible for inclusion in 
      this cross-sectional cohort study. Percentage of responses to questions related 
      to disease and treatment burden were counted for each category ("not at all" and 
      "a little" vs. "quite a bit" and "very much"). Additional demographic features 
      were derived from available medical records. A total of 111 patients (median age 
      of 74) responded to the ELD-14 questionnaire at onset of treatment and at the 
      2-year mark. Responses to EPIC questionnaires at matched follow-ups were scored 
      and correlated with the self-reported burden domain of the ELD-14 using the 
      Spearman correlation coefficient. Results: Number of patients reporting "quite a 
      bit" or "very much" burden from prostate cancer was 6.3% prior to treatment. This 
      was highest at 1-month (10.8%) and decreased to 9.0% at 24 months post-SBRT (X 
      (2) = 3.836, p = 0.6986). By comparison, 3.6 and 5.4% reported "quite a bit" or 
      "very much" burden from treatment at start of treatment and 24 months, 
      respectively (X (2) = 1.046, p = 0.9838). Patient reported treatment burden was 
      found to converge well with individual domains of EPIC-26. Patients undergoing 
      ADT experienced more burden than their non-ADT counterparts. Conclusions: This 
      cross-sectional study suggests a minority of patients reported high burden from 
      their clinically localized prostate cancer or from their SBRT treatment. 
      Self-reported burden converged well with lower EPIC scores in multiple domains.
CI  - Copyright (c) 2020 Aghdam, Pepin, Carrasquilla, Johnson, Danner, Ayoob, Yung, Lei, 
      Collins, Kumar, Suy, Lynch and Collins.
FAU - Aghdam, Nima
AU  - Aghdam N
AD  - Department of Radiation Medicine, Georgetown University Hospital, Washington, DC, 
      United States.
FAU - Pepin, Abigail
AU  - Pepin A
AD  - Department of Radiation Medicine, Georgetown University Hospital, Washington, DC, 
      United States.
AD  - George Washington School of Medicine and Health Sciences, Washington, DC, United 
      States.
FAU - Carrasquilla, Michael
AU  - Carrasquilla M
AD  - Department of Radiation Medicine, Georgetown University Hospital, Washington, DC, 
      United States.
FAU - Johnson, Colin
AU  - Johnson C
AD  - Department of Surgery, University of Southampton, Southampton, United Kingdom.
FAU - Danner, Malika
AU  - Danner M
AD  - Department of Radiation Medicine, Georgetown University Hospital, Washington, DC, 
      United States.
FAU - Ayoob, Marilyn
AU  - Ayoob M
AD  - Department of Radiation Medicine, Georgetown University Hospital, Washington, DC, 
      United States.
FAU - Yung, Thomas
AU  - Yung T
AD  - Department of Radiation Medicine, Georgetown University Hospital, Washington, DC, 
      United States.
FAU - Lei, Siyuan
AU  - Lei S
AD  - Department of Radiation Medicine, Georgetown University Hospital, Washington, DC, 
      United States.
FAU - Collins, Brian T
AU  - Collins BT
AD  - Department of Radiation Medicine, Georgetown University Hospital, Washington, DC, 
      United States.
FAU - Kumar, Deepak
AU  - Kumar D
AD  - Biotechnology Research Institute, North Carolina Central University, Durham, NC, 
      United States.
FAU - Suy, Simeng
AU  - Suy S
AD  - Department of Radiation Medicine, Georgetown University Hospital, Washington, DC, 
      United States.
FAU - Lynch, John
AU  - Lynch J
AD  - Department of Urology, Georgetown University Hospital, Washington, DC, United 
      States.
FAU - Collins, Sean P
AU  - Collins SP
AD  - Department of Radiation Medicine, Georgetown University Hospital, Washington, DC, 
      United States.
LA  - eng
PT  - Journal Article
DEP - 20200122
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC6987387
OTO - NOTNLM
OT  - SBRT
OT  - burden of disease
OT  - cyberknife
OT  - patient reported outcome (PRO)
OT  - prostate cancer
OT  - quality of life
EDAT- 2020/02/11 06:00
MHDA- 2020/02/11 06:01
PMCR- 2019/01/01
CRDT- 2020/02/11 06:00
PHST- 2019/09/17 00:00 [received]
PHST- 2019/12/18 00:00 [accepted]
PHST- 2020/02/11 06:00 [entrez]
PHST- 2020/02/11 06:00 [pubmed]
PHST- 2020/02/11 06:01 [medline]
PHST- 2019/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2019.01528 [doi]
PST - epublish
SO  - Front Oncol. 2020 Jan 22;9:1528. doi: 10.3389/fonc.2019.01528. eCollection 2019.